archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • News Archive
    Co Inc has submitted a Biologics License Application BLA for GARDASIL quadrivalent human papillomavirus types 6 11 16 18 recombinant vaccine to the U S Food and Drug Administration FDA on December 1 2005 More 07 10 2005 Investigational Vaccine Prevents 100 High Grade Cervical Pre Cancers and Non Invasive Cervical Cancers in Phase III Study CSL Limited announced today that GARDASIL an investigational vaccine developed by Merck Co Inc based on technology licensed from CSL prevented 100 percent of high grade cervical pre cancers and non invasive cervical cancers CIN 2 3 and AIS associated with human papillomavirus HPV types 16 and 18 which account for 70 percent of all cervical cancers More 24 08 2005 CSL Announces 2005 Full Year Results CSL today announced its operational results for the full year ended 30 June 2005 More 24 08 2005 CSL Limited enters into License and Option Agreement with Merck Co Inc for its Iscomatrix Adjuvant Technology CSL Limited Australia s leading biopharmaceutical company today announced that it has signed a license and option agreement with Merck Co Inc of Whitehouse Station New Jersey USA granting certain rights and options to Merck in a number of fields for the use of CSL s ISCOMATRIX adjuvant in Merck s pipeline of investigational vaccine products More 28 06 2005 Further Share Buyback Announced CSL Limited today announced its intention to conduct a further on market buyback of up to 8 million shares More 01 03 2005 CSL Completes Sale of JRH Biosciences CSL Limited announced today that it has completed the sale of its JRH Biosciences Division JRH to Sigma Aldrich Corporation for US 370m cash subject to normal closing adjustments More 23 02 2005 CSL Reports 160M First Half Result CSL Limited today announced its first half result for period

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1199979016380/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive


  • News Archive
    1999 News Archive 23 12 2004 Plasma Products Agreement Signed CSL Limited announced today that it has signed an agreement with the National Blood Authority acting on behalf of both State and Commonwealth Governments to continue to provide the Australian community with safe secure and affordable plasma therapeutic products More 26 08 2004 CSL Announces Full Year Results CSL Limited today announced its operating results for the full year ended 30 June 2004 More 26 08 2004 Dividend Reinvestment Plan Dividend Reinvestment Plan More 03 08 2004 2004 Earnings Expectations Clarified CSL Limited today announced that the company was now in a position to clarify the Group s overall earnings for the financial year 2004 following the purchase and ongoing integration of Aventis Behring This follows on from CSL s update to the market in May this year when the company said it was unable to provide an accurate earnings forecast for 2004 More 20 07 2004 CSL Appoints New Director CSL today announced that Mr Maurice Renshaw had been appointed a Director and would join the CSL Board effective immediately More 27 05 2004 S A F E Study confirms ALBUMEX can be used safely in fluid resuscitation CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1199979016359/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    this section 2012 News Archive 2011 News Archive 2010 News Archive 2009 News Archive 2008 News Archive 2007 News Archive 2006 News Archive 2005 News Archive 2004 News Archive 2002 News Archive 2001 News Archive 2000 News Archive 1999 News Archive 10 10 2003 CSL Completes Equity Raising CSL Limited today announced the successful closure of the institutional component of the equity raising that forms part of the funding package

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1199979016320/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive Newsroom 2002 2002 Releases Also in this section 2012 News Archive 2011 News Archive 2010 News Archive 2009 News Archive 2 2008 News Archive 2007 News Archive 2006 News Archive 2005 News Archive 2004 News Archive 2003 News Archive 2001 News Archive 2000 News Archive 1999 News Archive 21 08 2002 CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1199979016300/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive Newsroom 2001 2001 Releases Also in this section 2012 News Archive 2011 News Archive 2010 News Archive 2009 News Archive 2008 News Archive 2007 News Archive 2006 News Archive 2005 News Archive 2004 News Archive 2003 News Archive 2002 News Archive 2000 News Archive 1999 News Archive 22 08 2001 CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1199979016278/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive Newsroom 1999 1999 Releases Also in this section 2012 News Archive 2011 News Archive 2010 News Archive 2009 News Archive 2008 News Archive 2007 News Archive 2006 News Archive 2005 News Archive 2004 News Archive 2003 News Archive 2002 News

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1199979016189/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • CSL Historical Financial Performance in US Dollars
    US dollar reporting commencing with the 2012 13 financial year US dollars are the pharmaceutical industry standard currency for reporting purposes The move also reflects the increasing predominance of the Company s worldwide sales and operations in US dollars To assist investors during the transition the Company is today lodging with the Australian Securities Exchange sets of financial statements for the first half and full year financial 2012 restated in US dollars A 5 year financial summary in US dollars is also provided The financial statements have been prepared using Accounting Policies consistent with those applied in the preparation of CSL Limited s audited consolidated financial statements for these periods These accounting policies can be found in Note 1 of the CSL Limited Financial Report contained in the CSL Annual Report for the relevant period and available from the company s website www csl com au The attached financial statements are unaudited but have been subject to Agreed Upon Procedures carried out by Ernst Young We expect these to form the prior comparable period disclosures in the CSL Group Financial Statements for the half year ended 31 December 2012 to be reviewed by Ernst Young and full year ended 30

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255930016847/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL drug candidate in diabetes research breakthrough
    said Dr Andrew Nash Senior Vice President of Research at CSL This disease is reaching epidemic proportions and is a significant public health burden We are very hopeful that the antibody based drug that we have developed and tested together with Professor Eriksson will ultimately lead to a new treatment option for people with diabetes Type 2 diabetes is normally preceded by insulin resistance which is most often caused by obesity When this happens the cells no longer respond sufficiently to insulin which leads to elevated levels of blood sugar Dr Nash said insulin resistance is related to the storage of fat in the wrong places such as the muscles and in the heart although exactly how this relationship works is not fully understood What scientists do know however is that the VEGF B protein affects the transport and storage of fat in body tissue This was discovered by Professor Ulf Eriksson s research group in a study published in Nature in 2010 These findings were further developed in this latest study in which VEGF B signalling was blocked by CSL s drug candidate known as 2H10 in groups of diabetic mice and rats It s a great feeling to have published these new results said Professor Ulf Eriksson We discovered VEGF B back in 1995 and since then the VEGF B project has been a lengthy sojourn in the wilderness but now we re making one important discovery after the other A total of four related studies are reported in the Nature paper In one study mice bred to spontaneously develop diabetes were treated with 2H10 The mice subsequently developed neither insulin resistance nor diabetes The research team also crossed this mouse model with one that lacked the ability to produce VEGF B and found that the at risk

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255929822075/prdetail.htm (2014-01-05)
    Open archived version from archive